An Efficacy and Safety Study of Rimonabant for Treatment of Nonalcoholic Steatohepatitis (NASH) in Patients Without Diabetes

Stopped Company decision taken in light of demands by certain national health authorities

Conditions

• Fatty Liver

Interventions

• DRUG: Rimonabant
• DRUG: Placebo (for Rimonabant)

Sponsor

Sanofi